Clinical Scenario: A PD-L1-Low Patient with NSCLC

Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Data from the phase 3 PALOMA-3 study support the approval of subcutaneous amivantamab in this NSCLC population.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Experts discuss the proper placement of Dato-DXd in the treatment of EGFR-mutated non–small cell lung cancer, comparing it with other potential treatments.

Patients with squamous NSCLC who received ivonescimab plus chemotherapy as first-line treatment had delayed deterioration in global health status.